These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 23299792)

  • 1. Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors.
    Ferron GM; Dai Y; Semiond D
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):681-92. PubMed ID: 23299792
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Identification of Patients at Risk of Cabazitaxel-induced Severe Neutropenia.
    Agema BC; Buck SAJ; Viskil M; Isebia KT; de Neijs MJ; Sassen SDT; Koch BCP; Joerger M; de Wit R; Koolen SLW; Mathijssen RHJ
    Eur Urol Oncol; 2024 Aug; 7(4):786-793. PubMed ID: 37925350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer.
    Slaviero KA; Clarke SJ; McLachlan AJ; Blair EY; Rivory LP
    Br J Clin Pharmacol; 2004 Jan; 57(1):44-53. PubMed ID: 14678339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A pharmacokinetic model for amiodarone in infants developed from an opportunistic sampling trial and published literature data.
    Dallefeld SH; Atz AM; Yogev R; Sullivan JE; Al-Uzri A; Mendley SR; Laughon M; Hornik CP; Melloni C; Harper B; Lewandowski A; Mitchell J; Wu H; Green TP; Cohen-Wolkowiez M
    J Pharmacokinet Pharmacodyn; 2018 Jun; 45(3):419-430. PubMed ID: 29435949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Population pharmacokinetics of TLD-1, a novel liposomal doxorubicin, in a phase I trial.
    Mc Laughlin AM; Hess D; Michelet R; Colombo I; Haefliger S; Bastian S; Rabaglio M; Schwitter M; Fischer S; Eckhardt K; Hayoz S; Kopp C; Klose M; Sessa C; Stathis A; Halbherr S; Huisinga W; Joerger M; Kloft C
    Cancer Chemother Pharmacol; 2024 Sep; 94(3):349-360. PubMed ID: 38878207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic model for oral ORIN1001 in Chinese patients with advanced solid tumors.
    Li X; Bo Y; Zeng Q; Diao L; Greene S; Patterson J; Liu L; Yang F
    Front Pharmacol; 2024; 15():1322557. PubMed ID: 38500768
    [No Abstract]   [Full Text] [Related]  

  • 7. Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial.
    Bahl A; Oudard S; Tombal B; Ozgüroglu M; Hansen S; Kocak I; Gravis G; Devin J; Shen L; de Bono JS; Sartor AO;
    Ann Oncol; 2013 Sep; 24(9):2402-8. PubMed ID: 23723295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sequencing of Cabazitaxel and Abiraterone Acetate After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Treatment Patterns and Clinical Outcomes in Multicenter Community-Based US Oncology Practices.
    Sonpavde G; Bhor M; Hennessy D; Bhowmik D; Shen L; Nicacio L; Rembert D; Yap M; Schnadig I
    Clin Genitourin Cancer; 2015 Aug; 13(4):309-318. PubMed ID: 25743206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CAST: A retrospective analysis of cabazitaxel and abiraterone acetate sequential treatment in patients with metastatic castrate-resistant prostate cancer previously treated with docetaxel.
    Wissing MD; Coenen JL; van den Berg P; Westgeest HM; van den Eertwegh AJ; van Oort IM; Bos MM; Bergman AM; Hamberg P; Ten Tije AJ; Los M; Lolkema MP; de Wit R; Gelderblom H
    Int J Cancer; 2015 Mar; 136(6):E760-72. PubMed ID: 25242736
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.
    Angelergues A; Maillet D; Fléchon A; Ozgüroglu M; Mercier F; Guillot A; Le Moulec S; Gravis G; Beuzeboc P; Massard C; Fizazi K; de La Motte Rouge T; Delanoy N; Elaidi RT; Oudard S
    Eur J Cancer; 2014 Jun; 50(9):1602-9. PubMed ID: 24725337
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
    Bracarda S; Gernone A; Gasparro D; Marchetti P; Ronzoni M; Bortolus R; Fratino L; Basso U; Mazzanti R; Messina C; Tucci M; Boccardo F; Cartenì G; Pinto C; Fornarini G; Mattioli R; Procopio G; Chiuri V; Scotto T; Dondi D; Di Lorenzo G
    Future Oncol; 2014 May; 10(6):975-83. PubMed ID: 24295376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy.
    Halabi S; Armstrong AJ; Sartor O; de Bono J; Kaplan E; Lin CY; Solomon NC; Small EJ
    J Clin Oncol; 2013 Nov; 31(31):3944-50. PubMed ID: 24101043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I dose-finding study of cabazitaxel administered weekly in patients with advanced solid tumours.
    Fumoleau P; Trigo JM; Isambert N; Sémiond D; Gupta S; Campone M
    BMC Cancer; 2013 Oct; 13():460. PubMed ID: 24099585
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of cabazitaxel as second-third line treatment in patients with metastatic adrenocortical carcinoma.
    Laganà M; Grisanti S; Ambrosini R; Cosentini D; Abate A; Zamparini M; Ferrari VD; Gianoncelli A; Turla A; Canu L; Terzolo M; Tiberio GAM; Sigala S; Berruti A
    ESMO Open; 2022 Apr; 7(2):100422. PubMed ID: 35272132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal and Cardiovascular Toxicities by New Systemic Treatments for Prostate Cancer.
    Saltalamacchia G; Frascaroli M; Bernardo A; Quaquarini E
    Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32630204
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Androgen Receptor Splice Variant 7 Drives the Growth of Castration Resistant Prostate Cancer without Being Involved in the Efficacy of Taxane Chemotherapy.
    Shimizu Y; Tamada S; Kato M; Hirayama Y; Takeyama Y; Iguchi T; Sadar MD; Nakatani T
    J Clin Med; 2018 Nov; 7(11):. PubMed ID: 30453546
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing a Preclinical Multidisciplinary Board for Brain Tumors.
    Nimmervoll BV; Boulos N; Bianski B; Dapper J; DeCuypere M; Shelat A; Terranova S; Terhune HE; Gajjar A; Patel YT; Freeman BB; Onar-Thomas A; Stewart CF; Roussel MF; Guy RK; Merchant TE; Calabrese C; Wright KD; Gilbertson RJ
    Clin Cancer Res; 2018 Apr; 24(7):1654-1666. PubMed ID: 29301833
    [No Abstract]   [Full Text] [Related]  

  • 18. Towards better dose individualisation: metabolic phenotyping to predict cabazitaxel pharmacokinetics in men with prostate cancer.
    Janssen A; Verkleij CPM; van der Vlist A; Mathijssen RHJ; Bloemendal HJ; Ter Heine R
    Br J Cancer; 2017 May; 116(10):1312-1317. PubMed ID: 28399110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of cabazitaxel in patients with hepatic impairment: a phase I dose-escalation study.
    Sarantopoulos J; Mita AC; He A; Wade JL; Hsueh CT; Morris JC; Lockhart AC; Quinn DI; Hwang J; Mier J; Zhang W; Wack C; Yin J; Clot PF; Rixe O
    Cancer Chemother Pharmacol; 2017 Feb; 79(2):339-351. PubMed ID: 28058445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I/II trial of cabazitaxel plus abiraterone in patients with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and abiraterone.
    Massard C; Mateo J; Loriot Y; Pezaro C; Albiges L; Mehra N; Varga A; Bianchini D; Ryan CJ; Petrylak DP; Attard G; Shen L; Fizazi K; de Bono J
    Ann Oncol; 2017 Jan; 28(1):90-95. PubMed ID: 28039155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.